Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer
Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer
Bio2RDF identifier
NCT00470574
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00470574
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Vaccines may ...... ith metastatic breast cancer.
brief title [clinicaltrials_vocabulary:brief-title]
Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2016-03-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES:
Prim ...... are followed every 3 months.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2007-05-03T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
male breast cancer
recurrent breast cancer
stage IV breast cancer
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2015-03-24T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00470574
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
Pilot Study of Immunization of ...... e Immunological Adjuvant QS-21
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2016-03-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
P30CA008748
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2007-03-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2015-03-01T00:00:00Z
identifier
clinicaltrials:NCT00470574
title
Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer
@en